Reuters logo
Regeneron 4th-quarter profit beats on rising Eylea sales
February 14, 2013 / 11:55 AM / in 5 years

Regeneron 4th-quarter profit beats on rising Eylea sales

Feb 14 (Reuters) - Regeneron Pharmaceuticals Inc’s quarterly profit beat market estimates for the sixth straight quarter as sales of its eye drug Eylea continued to zoom.

The company posted a fourth-quarter net profit of $470 million, or $4.08 per share, compared with a net loss of $53.4 million, or 58 cents per share, a year earlier.

The company’s adjusted profit of $1.22 per share, according to Thomson Reuters I/B/E/S, beat analysts’ estimates of $1.10 per share.

Total revenue for the quarter more than tripled to $414.6 million.

Eylea, which is co-marketed by Germany’s Bayer AG , raked in U.S. sales of $276 million.

Analysts expected revenue of $392.6 million.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below